Back to Results New Search

Hyroxyurea

Drug Class: Antineoplastics and Related Agents
Dosage Form: Capsule
Strength: 500mg
Indications/Special comments: Treatment of metastatic disease, chronic myeloid leukaemia, haemoglobinopathies including sickle cell disease and tumours of the head and neck, an adjunct to nucleoside reverse transcriptase inhibitor in the treatment of HIV disease.
Dosage Administration: (Refer to individual protocols): Adult: Solid tumours: Intermittent therapy: 80mg/kg as a single dose every third day. Continuous therapy: 20 - 30mg/kg/day given as a single dose/day. Concomitant therapy with irradiation: 80mg/kg as a single dose every third day starting at least 7 days before initiation of irradiation. Resistant chronic myelocytic leukemia: Continuous therapy: 20 - 30mg/kg as a single daily dose. HIV (in combination with ARV agents): 1000 - 1500mg daily in a single dose or divided doses. Sickle cell anaemia: Initial: 15mg/kg/day, increased by 5mg/kg every 12 weeks if blood counts are in an acceptable range until the maximum tolerated dose of 35mg/kg/day is achieved.